Internal Medicine | Page 180 of 487 | Links Medicus Content Curation & Alerts in Medicine

Nice review of Periop mgmt for hip Fx. Uses a modified CCS guideline approach-no stress testing,bypass BNP as pts are high risk,postop co-mgmt +troponin. Also discusses other aspects. Major take home point – AVOID DELAYING SURGERY or mortality increases. https://t.co/5DATCuKuqU

— Steven Cohn, MD (@preopconsult) August 9, 2021

Review: Diseases and complications of the puerperium.

10 Aug, 2021 | 08:46h | UTC

Diseases and Complications of the Puerperium – Deutsches Ärzteblatt International

Plant-based diets protective against CVD in two cohort studies.

10 Aug, 2021 | 08:48h | UTC

Plant-Based Diets Protective Against CVD in Two Studies – TCTMD

Original study 1: Relationship Between a Plant‐Based Dietary Portfolio and Risk of Cardiovascular Disease: Findings From the Women’s Health Initiative Prospective Cohort Study – Journal of the American Heart Association

Original study 2: Plant‐Centered Diet and Risk of Incident Cardiovascular Disease During Young to Middle Adulthood – Journal of the American Heart Association

Interactive infographic: Data shows how rare severe breakthrough Covid infections are.

9 Aug, 2021 | 00:01h | UTC

Data shows how rare severe breakthrough Covid infections are – NBC News

Commentary on Twitter

Very good interactive infographic for impact of vaccination in 2021 by state https://t.co/HAfYYPX9FI by @NBCNews @seenigel @ChicagoEl @pdrbarquinha @jiachuanwu @NBCNewsGraphics
Here for California: Hospitalizations, deaths and infections pic.twitter.com/83Hxl2x2gm

— Eric Topol (@EricTopol) August 7, 2021

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

9 Aug, 2021 | 00:06h | UTC

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial – The Lancet

Invited commentary: Optimising SARS-CoV-2 vaccination schedules – The Lancet

Related: Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)

Commentary on Twitter

Just published @TheLancet
A randomized mix and match trial of AZ and Pfizer vaccination in >800 people shows that mixing is safe and can engender at least as good, if not better, immune response https://t.co/V40Dy59Ia8 by @XinxueLiu and colleagues pic.twitter.com/tKl59LFz4i

— Eric Topol (@EricTopol) August 6, 2021

Bullous autoimmune dermatoses: clinical features, diagnostic evaluation, and treatment options.

10 Aug, 2021 | 08:44h | UTC

Bullous Autoimmune Dermatoses – Deutsches Ärzteblatt International

CDC study showed a reduced risk of reinfection with SARS-CoV-2 after covid-19 vaccination.

9 Aug, 2021 | 00:03h | UTC

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 – CDC Morbidity and Mortality Weekly Report

Commentaries on Twitter

This is non randomized. The two biases are:

1. Behavior among those who got vaccinated likely different than those who don't

2. Likely those who didn't tested more aggressively

I would not cite this as many are doinghttps://t.co/rSkBC37uq0

— Vinay Prasad MD MPH (@VPrasadMDMPH) August 7, 2021

Study shows that full #COVIDVaccination ⬇️ likelihood of being re-infected with #COVID19 compared to those who were previously had COVID but were not vaccinated (risk ⬆️ 2.3 fold)#GetVaccinated even if you have had COVID previouslyhttps://t.co/3dF3XPxwYp

@fascinatorfun pic.twitter.com/ip6zTvNN86

— Prof Kamlesh Khunti (@kamleshkhunti) August 7, 2021

More data showing one dose of Pfizer vaccine may be enough for individuals who’ve had COVID.

8 Aug, 2021 | 23:50h | UTC

Commentary: One Dose of Pfizer Vaccine May Be Enough for Folks Who’ve Had COVID – HealthDay

Original Study: SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine – JAMA Network Open

Perspective | Is one vaccine dose enough if you’ve had COVID? What the science says.

Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19

Spain to give just one vaccine dose to under 55-year olds who had COVID-19

Perspective: Is one vaccine dose enough after COVID-19 infection?

France’s health authority recommends single vaccine shot for people who have had COVID-19

Covid-19: People who have had infection might only need one dose of mRNA vaccine

Commentary on Twitter

SARS-CoV-2 Antibody Responses After 1 and 2 Doses of the BNT162b2 Vaccine https://t.co/ARMdH8Yboo via @JAMANetworkOpen part of @JAMANetwork Small study but one that confirms the policy of many European countries in which one dose of vaccine is sufficient after having COVID.

— Carlos del Rio (@CarlosdelRio7) August 7, 2021

Case report: Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination.

8 Aug, 2021 | 23:49h | UTC

Systemic capillary leak syndrome afer ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination – Canadian Medical Association Journal

M-A: Effect of low glycemic index or load dietary patterns on glycemic control and cardiometabolic risk factors in diabetes.

8 Aug, 2021 | 23:42h | UTC

Effect of low glycaemic index or load dietary patterns on glycaemic control and cardiometabolic risk factors in diabetes: systematic review and meta-analysis of randomised controlled trials – The BMJ

Commentary: Low glycaemic diet shows meaningful improvements for people with diabetes – The British Medical Journal

Commentary on Twitter

New #BMJResearch finds that low glycaemic index/glycaemic load dietary patterns provide small important benefits for glycaemic control and other established cardiometabolic risk factors in adults with moderately controlled type 1 and type 2 diabeteshttps://t.co/EIMXUhICee

— The BMJ (@bmj_latest) August 7, 2021

M-A: Colchicine in patients with coronary artery disease – “colchicine reduces the risk of myocardial infarction and stroke, but has a higher rate of gastrointestinal upset with no influence on all‐cause mortality”.

8 Aug, 2021 | 23:40h | UTC

Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta‐Analysis of Randomized Trials – Journal of the American Heart Association

Review: Colchicine and the heart.

M-A: Colchicine administration for percutaneous coronary intervention

M-A: Efficacy and safety of low-dose colchicine in patients with coronary disease

Meta-analysis: Colchicine reduces new cardiovascular events in patients with coronary artery disease

Expert analysis: Efficacy and safety of colchicine in patients with chronic stable coronary disease

#ESCCongress – [Abstract Only] Randomized trial: Colchicine in patients with chronic coronary disease

#ESCCongress – Randomized trial: Colchicine not beneficial for patients with acute coronary syndrome

#ESCCongress – Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

#AHA19 – [Abstract Only] Practice Changing? – Randomized Trial: Low-Dose Colchicine Improves Outcomes after Myocardial Infarction

Research: Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome

Perspective: Does Treating Sleep Apnea With CPAP Improve Cardiovascular Outcomes or Lower Risk of Atrial Fibrillation? – “Despite numerous flawed observational studies suggesting an association between sleep apnea and cardiovascular outcomes including atrial fibrillation the gold standard, high-quality RCT data do not clearly show that treatment of sleep apnea with CPAP improves cardiovascular outcomes”.

8 Aug, 2021 | 23:31h | UTC

Does Treating Sleep Apnea With CPAP Improve Cardiovascular Outcomes or Lower Risk of Atrial Fibrillation? – The Skeptical Cardiologist

AHA Scientific Statement: Obstructive Sleep Apnea and Cardiovascular Disease.

Non-sleepy Obstructive Sleep Apnea: To Treat or Not to Treat?

Pro/Con Debate: Should Asymptomatic Patients with Moderate-to-severe OSA be Treated?

Obstructive Sleep Apnea in Cardiovascular Disease: A Review of the Literature and Proposed Multidisciplinary Clinical Management Strategy

Positive airway pressure doesn’t reduce cardiovascular events and death in adults with sleep apnea

[Preprint] RCT: non-invasive respiratory strategies in acute respiratory failure in patients with COVID-19 – CPAP reduced the composite outcome of intubation or death within 30 days; high-flow nasal oxygenation was not associated with better outcomes.

6 Aug, 2021 | 10:18h | UTC

An adaptive randomized controlled trial of non-invasive respiratory strategies in acute respiratory failure patients with COVID-19 – medRxiv

Commentary: Covid: Pressured oxygen reduces ventilator need – BBC

Commentary on Twitter (thread – click for more)

RECOVERY-RS results out, and confirm what most of us have been doing:

CPAP reduces intubation/mortality by 28% compared with no CPAP/HFNO (composite outcome, mostly intubation)
Nasal high flow not so successful

1/https://t.co/bcB2sTdAsu pic.twitter.com/fvT8IbyxUr

— 𝚃𝚘𝚖 𝙻𝚊𝚠𝚝𝚘𝚗 💙 (@LawtonTri) August 5, 2021

Antibody-mediated autoimmune encephalitis: A practical approach.

8 Aug, 2021 | 23:29h | UTC

Antibody-mediated autoimmune encephalitis: A practical approach – Cleveland Clinic Journal of Medicine

Perspective | Expertise from outside the Academy: tapering off antidepressants.

8 Aug, 2021 | 23:27h | UTC

Expertise from outside the Academy: tapering off antidepressants – The Mental Elf

A method for tapering antipsychotic treatment that may minimize the risk of relapse

Systematic Review: Managing Antidepressant Discontinuation

Randomized controlled trial: preventive cognitive therapy for prevention of depressive recurrence

M-A: Continuation of antidepressants vs. sequential psychological interventions to prevent relapse in depression.

Systematic Review: “Remdesivir probably has little or no effect on all‐cause mortality at up to 28 days in hospitalized adults with SARS‐CoV‐2 infection. We are uncertain about the effects of remdesivir on clinical improvement and worsening”.

6 Aug, 2021 | 10:15h | UTC

Remdesivir for the treatment of COVID‐19 – Cochrane Library

Summary: Remdesivir for the treatment of COVID-19 – Cochrane Library

Commentary on Twitter (thread – click for more)

JUST PUBLISHED – Is #remdesivir an effective treatment for #COVID19? https://t.co/ntgfDQjMqs This @CochraneHaem systematic review looked at this antiviral medicine to see if it's an effective treatment for people in hospital w #COVID & if it causes unwanted effects. 1/5 pic.twitter.com/UtIW83uTtn

— The Cochrane Library (@CochraneLibrary) August 5, 2021